Caris Life Sciences Welcomes Providence Swedish Cancer Institute to Precision Oncology Alliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: PRnewswire
- Collaboration Expansion: Caris Life Sciences announced the addition of Providence Swedish Cancer Institute and the Paul G. Allen Research Center to its Precision Oncology Alliance, increasing membership to 99 institutions and enhancing its influence in cancer research.
- Commitment to Innovation: The Providence Swedish Cancer Institute focuses on innovative cancer diagnosis and treatment, striving to provide patients with earlier access to promising therapies, which is expected to improve patient outcomes significantly.
- Resource Sharing: By leveraging shared resources, Caris POA members can accelerate access to leading-edge therapies, utilizing Caris' AI and machine learning technologies to advance precision oncology and improve clinical outcomes.
- Data Advantage: Caris offers a multimodal database containing billions of data points, supporting molecular profiling for cancer patients, enabling healthcare institutions to prioritize therapeutic options and enhance clinical trial opportunities.
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAI is 37.60 USD with a low forecast of 30.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 25.480
Low
30.00
Averages
37.60
High
45.00
Current: 25.480
Low
30.00
Averages
37.60
High
45.00
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
